Alembic Pharmaceuticals Bilan de santé
Santé financière contrôle des critères 6/6
Alembic Pharmaceuticals possède un total de capitaux propres de ₹48.9B et une dette totale de ₹9.9B, ce qui porte son ratio d'endettement à 20.4%. Son actif total et son passif total sont ₹72.3B et de ₹23.4B. L'EBIT de Alembic Pharmaceuticals est ₹7.2B ce qui fait que son ratio de couverture des intérêts 12.9. Elle dispose de liquidités et de placements à court terme de ₹1.3B.
Informations clés
20.4%
Ratio d'endettement
₹9.95b
Dette
| Ratio de couverture des intérêts | 12.9x |
| Argent liquide | ₹1.29b |
| Fonds propres | ₹48.88b |
| Total du passif | ₹23.43b |
| Total des actifs | ₹72.30b |
Mises à jour récentes de la santé financière
Is Alembic Pharmaceuticals (NSE:APLLTD) Using Too Much Debt?
Sep 03
Alembic Pharmaceuticals (NSE:APLLTD) Seems To Use Debt Rather Sparingly
Jun 03Is Alembic Pharmaceuticals (NSE:APLLTD) A Risky Investment?
Jan 05Here's Why Alembic Pharmaceuticals (NSE:APLLTD) Can Manage Its Debt Responsibly
Sep 27Alembic Pharmaceuticals (NSE:APLLTD) Seems To Use Debt Quite Sensibly
Jun 09Is Alembic Pharmaceuticals (NSE:APLLTD) A Risky Investment?
Feb 22Recent updates
Earnings Miss: Alembic Pharmaceuticals Limited Missed EPS By 5.6% And Analysts Are Revising Their Forecasts
Nov 10Alembic Pharmaceuticals Limited's (NSE:APLLTD) Intrinsic Value Is Potentially 17% Below Its Share Price
Sep 25Is Alembic Pharmaceuticals (NSE:APLLTD) Using Too Much Debt?
Sep 03Alembic Pharmaceuticals Limited Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
Aug 13Market Participants Recognise Alembic Pharmaceuticals Limited's (NSE:APLLTD) Earnings Pushing Shares 25% Higher
Jul 20Alembic Pharmaceuticals (NSE:APLLTD) Seems To Use Debt Rather Sparingly
Jun 03Does This Valuation Of Alembic Pharmaceuticals Limited (NSE:APLLTD) Imply Investors Are Overpaying?
May 11Results: Alembic Pharmaceuticals Limited Exceeded Expectations And The Consensus Has Updated Its Estimates
Feb 08Subdued Growth No Barrier To Alembic Pharmaceuticals Limited (NSE:APLLTD) With Shares Advancing 25%
Jan 21Is Alembic Pharmaceuticals (NSE:APLLTD) A Risky Investment?
Jan 05Here's Why Alembic Pharmaceuticals (NSE:APLLTD) Can Manage Its Debt Responsibly
Sep 27Alembic Pharmaceuticals (NSE:APLLTD) Seems To Use Debt Quite Sensibly
Jun 09A Look At The Fair Value Of Alembic Pharmaceuticals Limited (NSE:APLLTD)
Apr 13Is Alembic Pharmaceuticals (NSE:APLLTD) A Risky Investment?
Feb 22Alembic Pharmaceuticals Limited (NSE:APLLTD) Shares Could Be 21% Below Their Intrinsic Value Estimate
Jan 04We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Alembic Pharmaceuticals Limited's (NSE:APLLTD) CEO For Now
Nov 05Here's Why Alembic Pharmaceuticals (NSE:APLLTD) Has A Meaningful Debt Burden
Aug 10Estimating The Intrinsic Value Of Alembic Pharmaceuticals Limited (NSE:APLLTD)
Jul 20Analyse de la situation financière
Passif à court terme: Les actifs à court terme de APLLTD ( ₹37.6B ) dépassent ses passifs à court terme ( ₹21.7B ).
Passif à long terme: Les actifs à court terme de APLLTD ( ₹37.6B ) dépassent ses passifs à long terme ( ₹1.7B ).
Historique et analyse du ratio d'endettement
Niveau d'endettement: Le ratio dette nette/capitaux propres de APLLTD ( 17.7% ) est considéré comme satisfaisant.
Réduire la dette: Le ratio d'endettement de APLLTD a été réduit de 51.8% à 20.4% au cours des 5 dernières années.
Couverture de la dette: La dette de APLLTD est bien couverte par le flux de trésorerie opérationnel ( 41.1% ).
Couverture des intérêts: Les paiements d'intérêts de APLLTD sur sa dette sont bien couverts par l'EBIT ( 12.9 x couverture).